Optimising managed access: lessons from the Cancer Drugs Fund


14 May 2021 - The desire, opportunity, and willingness to increase access to potentially life saving cancer treatments has mounted in recent years. As the landscape of drug development changes, the criteria for evaluating uncertainty must also change. 

Some believe the Cancer Drugs Fund framework should be evaluated to ensure it can operate to its full potential. 

In this article, the authors explore potential changes to both the processes and infrastructure of managed access in England as a means of optimising access for patients.

Read Value & Outcomes Spotlight article

Michael Wonder

Posted by:

Michael Wonder